

Figure S1. Effects of U0126, SB202190 and SP600125 on OPG-mediated osteoclast adhesion structures. Osteoclasts were pre-treated with U0126, SB202190 and SP600125 for 30 min followed by treatment with 80 ng/ml OPG for a further 12 h. Osteoclasts were fixed, permeabilized and stained for vinculin, paxillin, SRC and PYK2, actin, and nuclei. Colocalization of vinculin, paxillin, SRC and PYK2 were analyzed using a confocal fluorescence microscope. Scale bars, 20  $\mu$ m. OPG, osteoprotegerin; PYK2, phosphorylated protein tyrosine kinase 2.




Figure S2. Mature osteoclasts were pre-treated with BzATP for 30 min, followed by treatment with 80 ng/ml OPG for a further 12 h. The cells were transfected with negative control-shRNA and P2X7R-shRNA for 48 h, followed by treatment with OPG for 12 h. The distribution of vinculin, paxillin, SRC and PYK2 was analyzed using a confocal fluorescence microscope. Scale bars, 20  $\mu$ m. OPG, osteoprotegerin; PYK2, phosphorylated protein tyrosine kinase 2; P2X7R, purinergic receptor P2X7; BzATP, 3'-O-(4-Benzoyl) benzoyl ATP.

